Preventive Longevity Medicine Roundup: Funding, Deals and Early Research

A news roundup published by Longevity.Technology on June 19, 2026 gathered several developments across preventive longevity medicine, spanning fresh funding, a large pharmaceutical partnership, and early-stage research. The roundup was hosted by Longevity.Technology founder and chief executive Phil Newman and pharmacologist and entrepreneur Dr. Nina Patrick.

On the deal front, the roundup reported that Eli Lilly and AlzeCure Pharma entered an agreement potentially worth more than $1 billion, focused on a preventive Alzheimer's therapy aimed at disease processes years before symptoms emerge. Separately, the AI-focused aging-research company Gero was reported to have raised $17 million in new funding and to have expanded a collaboration with Chugai Pharmaceutical. According to the roundup, Gero works on physics-based models and large human datasets to identify potential therapeutic targets related to aging.

Several items concerned research described as preliminary. The roundup reported that Fractyl Health's REVEAL-1 study found patients maintained roughly 78% of GLP-1-related weight loss after its Revita procedure. The roundup framed this as raising the possibility of a long-term alternative while noting that controlled trials are still needed. It also cited peer-reviewed preclinical work from Immorta Bio reporting more than a 70% lifespan increase in a model when senescent cell clearance was combined with regenerative therapies, presented as support for the concept that multiple aging mechanisms may need to be addressed at once. These are laboratory and early clinical findings and have not been shown to be safe or effective treatments for general use.

The roundup also noted a campaign by the Longevity Science Foundation to accelerate ovarian aging research, which it described as underfunded relative to its relevance to female healthspan, and work by MuseCell Innovations on stress-resistant stem cell therapies for tissue repair.

The items above reflect company and organization statements reported in the roundup rather than independently verified outcomes. Where findings are preclinical or from single studies, they should be understood as early signals, not evidence of proven benefit. Readers should consult qualified medical professionals before making health decisions.

This article summarizes the Longevity.Technology roundup for week 25 of 2026. Figures and claims are attributed to that source.